European Primary Care Cardiovascular Society
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.
"During the pandemic, we have lost sight of long-term conditions that are the biggest contributors to worse outcomes", says prof. Hobbs. "We need to restart and catch up in CVD prevention ASAP."
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.
Despite its increasing popularity, time-restricted eating did not show more benefits in Chinese obese patients after one year than restricting calories alone.
In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.
A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.
An exploratory analysis showed that apixaban as extended treatment (>90 days) after hospitalization for venous thromboembolism (VTE) is associated with a lower rate of hospitalizations for recurrent VTE versus warfarin as extended treatment.
Lp(a) levels are thought to stay stable over time, at least in adults. As several lipid values change during childhood, Lp(a) values were measured in a large cohort of children. The result: Lp(a) levels increased with age.
This study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.
A randomized, controlled, crossover study showed that sleep restriction leads to excess calorie intake, weight gain and an increase in abdominal fat.
ACC 2022 Prof. Handberg shares and interprets the findings from the SuperWIN study. "We have the ability with this type of intervention to really impact multiple generations", she said.
